Navigation Links
Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
Date:2/11/2010

MOUNTAIN VIEW, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food & Drug Administration has accepted the AZ-004 NDA for filing and has indicated a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  Alexza filed the AZ-004 NDA on December 11, 2009 and is seeking marketing approval for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials.  In February 2010, Alexza established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation ( BVF), to develop and commercialize AZ-004 in the U.S. and Canada.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-004.  Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  Alexza's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in Alexza's Annual Report on Form 10-K for the year ended December 31, 2008, and Alexza's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the heading: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials." Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

RELATED LINKS
http://www.alexza.com

'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
2. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
3. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
4. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
5. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
6. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
7. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
8. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
9. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... development of oral drug delivery systems, announced today that ... to schedule an End-of-Phase II meeting with Oramed for ... insulin capsule ORMD-0801 in the treatment of type 2 ... endpoints by indicating a statistically significant lowering of glucose ...
(Date:7/10/2017)...  The tenth annual BioPharm America™ will ... at the Sheraton Boston Hotel, September 26–27. The event ... decision makers and innovative biotech startup companies. The event ... two impactful days. BioPharm America is now part of ... opportunities with 4,500+ life science industry influencers participating in ...
(Date:7/5/2017)... , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company focused ... that it has received approval from the Israel Securities Authority ... Exchange (TASE). Oramed common stock will commence trading on the ... on the current market capitalization of the Company, it is ...
Breaking Medicine Technology:
(Date:7/20/2017)... SANTA CLARA, CA (PRWEB) , ... July 20, ... ... some form of travel protection services since 2014, top travel insurance solution company ... agents the tools to sell all major international travel insurance products online, under ...
(Date:7/20/2017)... ... 2017 , ... A local summer theatre camp is celebrating ... support fine arts programs in Chester County’s Elementary Schools. In late June, students ... , More than 850 people attended the two performances, an increase from ...
(Date:7/20/2017)... ... ... Med Tech Solutions (MTS), a leading health care cloud computing company, recently announced ... move that will help the company better serve its clients and promote continued growth. ... to help MTS expand its presence in the Midwest and deepen MTS’ ...
(Date:7/20/2017)... ... 2017 , ... A July 5th article on Reuters Health News ... received a body contouring procedure reported experiencing a better quality of life, compared to ... provides both types of procedures, notes that this report jibes with what they regularly ...
(Date:7/20/2017)... ... ... the Buffalo and Her Adventures”: a collection of heartwarming children’s stories. “Lucky the Buffalo ... Jr. was born in Toledo, Ohio. He attended Woodward High School. He earned ... to a brilliant woman with a caring heart named Tiina, who is a hospice nurse. ...
Breaking Medicine News(10 mins):